Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update

Structure Therapeutics Inc. (NASDAQ:GPCR) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 10,750,000 shares, an increase of 5.8% from the December 31st total of 10,160,000 shares. Based on an average daily trading volume, of 824,600 shares, the short-interest ratio is currently 13.0 days. Currently, 19.8% of the shares of the company are sold short.

Structure Therapeutics Stock Performance

GPCR stock opened at $29.95 on Wednesday. The firm’s fifty day moving average is $29.54 and its 200 day moving average is $35.11. The firm has a market cap of $1.71 billion, a PE ratio of -40.47 and a beta of -2.76. Structure Therapeutics has a one year low of $23.50 and a one year high of $62.74.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP grew its stake in Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after acquiring an additional 221,851 shares during the period. FMR LLC raised its holdings in shares of Structure Therapeutics by 6.7% during the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after acquiring an additional 383,635 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Structure Therapeutics by 18.0% in the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after acquiring an additional 602,609 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Structure Therapeutics by 196.5% in the third quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after acquiring an additional 820,589 shares during the last quarter. Finally, Vestal Point Capital LP increased its position in shares of Structure Therapeutics by 105.4% during the third quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reaffirmed a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Stifel Nicolaus began coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price for the company. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics has an average rating of “Buy” and a consensus price target of $81.29.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.